HK1181846A1 - 新的卵巢癌生物標誌物和靶 - Google Patents

新的卵巢癌生物標誌物和靶

Info

Publication number
HK1181846A1
HK1181846A1 HK13109046.0A HK13109046A HK1181846A1 HK 1181846 A1 HK1181846 A1 HK 1181846A1 HK 13109046 A HK13109046 A HK 13109046A HK 1181846 A1 HK1181846 A1 HK 1181846A1
Authority
HK
Hong Kong
Prior art keywords
targets
ovarian carcinoma
novel biomarkers
biomarkers
novel
Prior art date
Application number
HK13109046.0A
Other languages
English (en)
Inventor
David G Huntsman
Marco Marra
Kimberly Wiegand
Martin Hirst
Sohrab Prakash Shah
Original Assignee
British Columbia Cancer Agency Branch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency Branch filed Critical British Columbia Cancer Agency Branch
Publication of HK1181846A1 publication Critical patent/HK1181846A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1079—Screening libraries by altering the phenotype or phenotypic trait of the host
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
HK13109046.0A 2010-04-22 2013-08-02 新的卵巢癌生物標誌物和靶 HK1181846A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32685910P 2010-04-22 2010-04-22
US36859610P 2010-07-28 2010-07-28
PCT/IB2011/051763 WO2011132175A2 (en) 2010-04-22 2011-04-22 Novel biomarkers and targets for ovarian carcinoma

Publications (1)

Publication Number Publication Date
HK1181846A1 true HK1181846A1 (zh) 2013-11-15

Family

ID=44834571

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13109046.0A HK1181846A1 (zh) 2010-04-22 2013-08-02 新的卵巢癌生物標誌物和靶

Country Status (7)

Country Link
US (1) US20130197056A1 (zh)
EP (1) EP2561351B1 (zh)
CN (1) CN103026227B (zh)
BR (1) BR112012027104B8 (zh)
CA (1) CA2797291C (zh)
HK (1) HK1181846A1 (zh)
WO (1) WO2011132175A2 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102808016B (zh) * 2011-05-30 2015-05-06 上海人类基因组研究中心 Arid1a基因及其编码蛋白产物的应用
CN102994630A (zh) * 2012-09-24 2013-03-27 中山大学达安基因股份有限公司 一种卵巢透明细胞癌诊断试剂盒及其制备方法
US20150252415A1 (en) * 2012-10-15 2015-09-10 The Children's Hospital Of Philadelphia Arid1b and neuroblastoma
WO2014150751A2 (en) 2013-03-15 2014-09-25 Novartis Ag Biomarkers associated with brm inhibition
WO2015143441A1 (en) * 2014-03-21 2015-09-24 The Translational Genomics Research Institute Compositions, methods and kits for characterizing and screening for small cell ovarian carcinoma
CA2946289C (en) * 2014-03-25 2018-08-07 Five3 Genomics, Llc Systems and methods for rna analysis in functional confirmation of cancer mutations
US11091810B2 (en) * 2015-01-27 2021-08-17 BioSpyder Technologies, Inc. Focal gene expression profiling of stained FFPE tissues with spatial correlation to morphology
CN104922697B (zh) * 2015-05-26 2018-02-27 复旦大学附属金山医院 降低磷酸吡哆醇氧化酶治疗卵巢癌
CN104906598B (zh) * 2015-06-01 2020-01-21 中南大学湘雅医院 ACTL6A基因shRNA敲除序列在制备治疗肝癌或术后预防肝癌复发药物中的应用
CN105461794A (zh) * 2015-12-16 2016-04-06 中国医科大学 Snf5在抑制肝癌方面的应用
WO2017132276A1 (en) * 2016-01-26 2017-08-03 Ventana Medical Systems, Inc. Predictive diagnostic workflow for tumors usnig automated dissection, next generation sequencing, and automated slide stainers
CN107858416B (zh) * 2016-09-19 2021-05-28 深圳华大生命科学研究院 用于子宫内膜异位症检测的生物标志物组合及其应用
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
CN108504637A (zh) * 2017-07-10 2018-09-07 复旦大学附属肿瘤医院 中国人卵巢透明细胞癌细胞系
CN112119156A (zh) * 2018-03-16 2020-12-22 杰傲湃思实验有限责任公司 个体化检测癌症复发或转移和/或评估治疗反应的方法
US20200063202A1 (en) * 2018-04-25 2020-02-27 Juneau Biosciences, L.L.C. Methods of using genetic markers associated with endometriosis
CN111269979A (zh) * 2020-02-06 2020-06-12 至本医疗科技（上海）有限公司 Arid1b基因变异在预测肺腺癌患者对免疫检查点抑制剂疗法敏感性中的应用
WO2021173960A1 (en) * 2020-02-28 2021-09-02 The Wistar Institute Of Anatomy And Biology Treatment of carm1-overexpressing and/or arid1a mutant cancers with ire-1/xbp-1 inhibitors
CN112301123B (zh) * 2020-11-17 2022-08-16 北京迈基诺基因科技股份有限公司 一种用于50种遗传病单基因突变检测的试剂盒及其使用的探针组
CN113046438B (zh) * 2021-03-26 2022-03-22 中国医学科学院北京协和医院 一种纳入分子分型和免疫评分的子宫内膜癌预后评价系统
CN114214418A (zh) * 2022-02-10 2022-03-22 上海交通大学医学院附属第九人民医院 一种评估肺癌患者对质子放疗敏感性的生物标志物及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1169753A (zh) * 1994-08-12 1998-01-07 亿万遗传股份有限公司 诊断乳房癌和卵巢癌倾向性的方法
EP1332367A2 (en) * 2000-11-01 2003-08-06 Mount Sinai Hospital Detection of ovarian cancer
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
EP1670350A4 (en) * 2003-10-07 2008-02-13 Millennium Pharm Inc NUCLEIC ACID MOLECULES AND PROTEINS FOR THE IDENTIFICATION, EVALUATION, PREVENTION AND TREATMENT OF OVARIAN CANCER
US20090176724A1 (en) * 2004-06-30 2009-07-09 Daiwei Shen Methods and Compositions for the Diagnosis, Prognosis and Treatment of Cancer
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors

Also Published As

Publication number Publication date
BR112012027104B1 (pt) 2020-01-14
CA2797291C (en) 2020-08-11
EP2561351B1 (en) 2015-12-09
EP2561351A4 (en) 2013-10-16
WO2011132175A3 (en) 2011-12-15
BR112012027104A2 (pt) 2016-11-16
CN103026227B (zh) 2015-09-30
US20130197056A1 (en) 2013-08-01
CA2797291A1 (en) 2011-10-27
BR112012027104B8 (pt) 2020-02-27
CN103026227A (zh) 2013-04-03
WO2011132175A2 (en) 2011-10-27
EP2561351A2 (en) 2013-02-27

Similar Documents

Publication Publication Date Title
HK1181846A1 (zh) 新的卵巢癌生物標誌物和靶
SG2014007454A (en) Pancreatic cancer biomarkers and uses thereof
IL252163A0 (en) Lung cancer biomarkers and their uses
IL223295A0 (en) Lung cancer biomarkers and uses thereof
EP2536854A4 (en) CUSTOMIZED TUMOR BIOMARKERS
GB201302520D0 (en) Compositions and methods for detecting cancer metastasis
HK1206414A1 (zh) 對胃癌的生物標記物及其用途
EP2625292A4 (en) KREBSBIOMARKER
GB201021502D0 (en) Biomarkers
GB201008340D0 (en) Biomarkers
GB201018056D0 (en) Biomarkers
EP2758777A4 (en) PROOF OF EGG CANCER
GB201005561D0 (en) Biomarkers
GB201001444D0 (en) Biomarkers
EP2771685A4 (en) KREBSBIOMARKER
WO2012167112A9 (en) Gastric cancer biomarkers
EP2596010A4 (en) SIGNALBIOMARKER
EP2630498A4 (en) PROGNOSTIC BIOMARKERS IN PATIENTS WITH OVARIAN CANCER
GB201004442D0 (en) Biomarker
EP2350917A4 (en) BIOMARKERS OF OVARIAN CANCER AND USES THEREOF
EP2554994A4 (en) BIOMARKERS
GB201010316D0 (en) Biomarkers
GB201005456D0 (en) Biomarkers
GB201004304D0 (en) Biomarkers for prostate cancer
GB201001419D0 (en) Biomarkers

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220422